Search Results

Randy Hall's study: GPR37L1's role in shaping cortical astrocytes during development Dr. From Indivior In Extended Substance Use Disorder Research Collaboration Addex Therapeutics To Release Half-Year 2023 Financial Results And Host Conference Call On August 10, 2023 X4 Pharmaceuticals Closes $115 Million hand Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half

Batman ) and master the Hall model  to decode the thermodynamics behind complex binding behavior . residual signal effects ✅ Tools to model binding with cooperativity factors (α, β, γ, σ) using the Hall Thermodynamics > Intuition: Why the Hall Cube Matters To untangle complex binding behaviors, you need Kenakin introduces the Hall model : a cube mapping allosteric and orthosteric interactions, layered with today ➤ #AllostericPharmacology #GPCR #BindingVsFunction #ReceptorPharmacology #DrugDiscoveryTools #HallModel

Michelle Halls This episode goes beyond the bench. Dr. Michelle Halls dissects how spatial GPCR signaling shifts discovery—and how leadership, mentorship, and signals today will shape tomorrow’s breakthroughs—and avoid delays others won’t see coming. 👉 Don’t Fall accelerate your next move. 🧭 Get smarter signal detection, sharper tools, and real-time intelligence—all

August 2022 "GPCRs in Medicinal Chemistry Event 8th RSC / SCI symposium on GPCRs in Medicinal Chemistry Dates Wednesday-Friday, 5th-7th October 2022 Place Evotec Campus Levi-Montalcini, Verona, Italy Downloads and Links Registration closing dates: 6th September – registration against invoice (bank transfers): Tuesday, 6th September 30th September – online registration (card payments)" Read more at the source #DrGPCR #GPCR #IndustryNews

August 2022 "WELCOME 4GPCRnet meeting bringing together four of the biggest GPCR networks in Europe for a joint meeting in Leipzig. Four of the biggest European networks on GPCR research (COST Actions Adher’n Rise and ERNEST plus DFG-funded SFB1423 and FOR2372) have joined forces to organize an international meeting, which will take place from 26th-29th September 2022 in the beautiful city of Leipzig in Germany. We aim to connect renowned international experts of the field with early career ‘rising stars’. The event will take place in the heart of Leipzig, which offers a colorful mixture of culture and vivid social life." Read more at the source #DrGPCR #GPCR #IndustryNews

August 2022 "Join Us in Boston for Discovery On Target 2022! Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules." Read more at the source #DrGPCR #GPCR #IndustryNews

August 2022 RAB-Symposium - Regulatory Autoantibodies Targeting GPCRs. September 15-16, 2022. Lübeck, Germany. Hybrid meeting. "Dear Sir or Madam, dear Colleagues, It gives me great pleasure to announce the fourth hybrid symposium on regulatory autoantibodies targeting G-protein-coupled receptors (GPCRs) in Lübeck. GPCRs are involved in a variety of physiological and pathophysiological processes. So far, numerous therapeutics targeting GPCRs have been developed, with a focus on small molecules and monoclonal antibodies for the treatment of cancer, infections, metabolic disorders or inflammatory diseases. Recently, functional autoantibodies targeting GPCRs have been associated with various disease-specific manifestations, highlighting a potential new area for therapeutic intervention. Therefore, the aim of this symposium is to bring together the current knowledge on the role of autoantibodies targeting GPCRs in various diseases, such as cardiovascular diseases, renal diseases, autoimmune diseases such as systemic sclerosis or systemic lupus erythematosus. In addition, one aim is to bring together the mode of action of autoantibodies in immune regulation and pathogenesis." Read more at the source #DrGPCR #GPCR #IndustryNews

August 2022 "We are happy to announce you our 2nd IRN i-GPCRnet meeting that will be held at the University of Wurzburg (Germany) from september 30th to october 1rst." Read more at the source #DrGPCR #GPCR #IndustryNews

Bursicon receptor gene HLGR2 as a potential RNA interference target for control of the fall webworm Hyphantria

pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its half-year

March 2022 "Geneva, Switzerland, March 7, 2022 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it will issue its full-year 2021 financial results on Thursday, March 10, 2022. Tim Dyer, CEO, Roger Mills, CMO and Robert Lütjens, Head of Discovery Biology, will provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 GMT / 10:00 EST / 07:00 PST) the same day. " Read more at the source #DrGPCR #GPCR #IndustryNews

The all-atom MD simulations reveal that CBD induces conformational changes linked with agonist-bound

I didn’t expect to love it, says Michelle Halls. It’s easy to call it luck. But luck only works if you say yes when the door opens. Built to Inspire The story of Michelle Halls isn’t just about a career; it’s about a pattern. For GPCR research, leaders like Michelle are showing what happens when we follow the signal all the way . 🎧 Listen to the full conversation with Michelle Halls on  The Dr.

It’s a call to see your lab bench not as a constraint, but as a launchpad. 🎧  Listen to the full conversation with Michelle Halls on the Dr.

October 2022 "Psychedelics, also known as classical hallucinogens, affect processes related to perception

Read more at the source #DrGPCR #GPCR #IndustryNews 5-HT2AR, GPCR, hallucinogens, in vitro assay, psychedelics

in dense receptor environments  amplifies target occupancy, even post-clearance ✅ Insight into why half-life Concentrations rise and fall. Clearance happens. And drugs only work when they’re bound. Why Half-Life Can Lie to You Most teams use systemic half-life as a proxy for action.

Drugs that look great in vitro fall apart in humans. A Call for Patient-First Science Serafini’s strategy isn’t just about method — it’s about mindset.

August 2022 "Psychedelic research across different disciplines and biological levels is growing at a remarkably fast pace. In the prospect of a psychedelic drug becoming again an approved treatment, much of these efforts have been oriented toward exploring the relationship between the actual psychedelic effects and those manifestations of therapeutic interest. Considering the central role of the serotonin 5-HT2A receptor in the distinct effects of psychedelics in human psyche, neuropharmacology sits at the center of this debate and exploratory continuum. Here we discuss some of the most recent findings in human studies and contextualize them considering previous preclinical models studying phenomena related to synaptic plasticity. A special emphasis is placed on knowledge gaps, challenges, and limitations to evaluate the underpinnings of psychedelics' potential antidepressant action." Read more at the source #DrGPCR #GPCR #IndustryNews

Eliminate subjective calls:  From t-tests to ANOVA and F-tests, know which tool to apply when, so debates Whether you’re in discovery, translation, or strategic leadership, Premium ensures you never fall behind signals today will lead tomorrow’s breakthroughs—and avoid delays others won’t see coming. 👉 Don’t Fall

Thank you to all participants in Dr. Terry Kenakin's educational initiative this fall! GPCR News  Let’s dive into the   Classified GPCR News from October 21st to 27th, 2024 Industry News Call

The family of adhesion GPCRs called the Latrophilins or ADGRLs first captured my attention due to their I still remember entering the Hall at Boston ́s Children Hospital, going to register and being asked Also, seeing the expanding diversity among the aGPCR community, added to the fact that this will all PMID 38421639 Systematic assessment of the tethered agonist-dependent activities of all 33 aGPCRs in

It was about what we could build together, recalls Michelle Halls.

Newfield, M.D., University of California, San Diego and Rady Children's Hospital, San Diego on June 13 company also presented data highlighting patient preferences and treatment patterns in classic CAH in Hall

I call it the Lego Bucket Problem : You’ve got CRO output, internal assay data, maybe even some promising True Embedded Partnership I review CRO scopes, flag risks early, and sit in on your strategic calls. execution, and a clear line of sight to your next key decision. 🚀 Book your free 30-minute strategy call

Thank you to all participants in Dr. Terry Kenakin's educational initiative this fall! We thank all participants for their inspiring contributions and passion. important drug breakthroughs ever Goldman-backed drug developer Septerna raises $288 mln in US IPO Call

The answer lies in a misunderstood property called efficacy—the power of a drug to trigger a response

For others, it’s a calling. The work no longer felt like an assignment—it felt like a calling. Catherine’s story shows that when purpose drives research, science becomes more than a job—it becomes a calling

Misreading Antagonism Delays GPCR Drug Discovery If a dose-response curve shifts to the right, you might call Fast offset kinetics allow agonists to outcompete and restore full activity—hallmarks of competitive

GPCR University offers two live courses this fall that you won’t want to miss. News Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half